DORYX Drug Patent Profile
When do Doryx patents expire, and when can generic versions of Doryx launch?
Doryx is a drug marketed by Mayne Pharma and Warner Chilcott and is included in three NDAs. There are four patents protecting this drug.
The generic ingredient in DORYX is doxycycline hyclate. There is one drug master file entry for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Doryx
A generic version of DORYX was approved as doxycycline hyclate by STRIDES PHARMA on March 29th, 1982.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DORYX?
- What are the global sales for DORYX?
- What is Average Wholesale Price for DORYX?
Summary for DORYX
| US Patents: | 1 |
| Applicants: | 2 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 57 |
| Patent Applications: | 4,624 |
| Drug Prices: | Drug price information for DORYX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DORYX |
| What excipients (inactive ingredients) are in DORYX? | DORYX excipients list |
| DailyMed Link: | DORYX at DailyMed |
Pharmacology for DORYX
| Drug Class | Tetracycline-class Drug |
US Patents and Regulatory Information for DORYX
DORYX is protected by one US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | DORYX | doxycycline hyclate | CAPSULE, DELAYED RELEASE;ORAL | 050582-002 | Aug 13, 2001 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mayne Pharma | DORYX | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 050795-002 | May 6, 2005 | DISCN | Yes | No | 8,715,724 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Mayne Pharma | DORYX | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 050795-006 | Dec 19, 2014 | DISCN | Yes | No | 8,715,724 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DORYX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mayne Pharma | DORYX | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 050795-002 | May 6, 2005 | 6,958,161 | ⤷ Start Trial |
| Mayne Pharma | DORYX | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 050795-006 | Dec 19, 2014 | 6,958,161 | ⤷ Start Trial |
| Mayne Pharma | DORYX | doxycycline hyclate | TABLET, DELAYED RELEASE;ORAL | 050795-003 | Jun 20, 2008 | 6,958,161 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DORYX
See the table below for patents covering DORYX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2005299253 | Improved tabletting process | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2006045152 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
DrugChatter Q&A for DORYX
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch